Navigation Links
New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders

In the latest studies that was presented yesterday at Digestive Disease Week? 2006 (DDW) are finding that long-term therapy with new compounds can sustain relief for these patients with symptoms ranging// from constipation to inflammation. These studies are conducted to review the therapeutic benefits for irritable bowel syndrome (IBS) and Crohn’s disease. They claim that the symptoms of the bowel disorders like IBS and Crohn's disease may vary in function and their severity. DDW is the largest international meeting of physicians and researchers in the fields of Gastroentrologist, Hepatology, Endoscopy and gastrointestinal surgery.

A Dose-Ranging, Double-Blind, Placebo-Controlled Study of Lubiprostone in Subjects with Irritable Bowel Syndrome and Constipation (c-IBS) [Abstract 131] Irritable bowel syndrome (IBS) affects millions of people in America and is difficult to diagnose and treat effectively due to its variability of symptoms. Current therapies work on select patient populations, but are limited in efficacy and have significant side effects. In this study, researchers examine the use of a novel therapy as an effective and safe new option for IBS patients.

Lubiprostone, a novel type-2 chloride channel (ClC-2) activator, has shown positive results and good tolerability in previous trials of patients with chronic constipation. The therapy increases fluid secretion, which works to improve function in the gastrointestinal system. This study tested different doses of lubiprostone over 12 weeks in subjects with constipation-specific IBS (c-IBS), as defined by the Rome II Criteria, which outlines symptoms and applies parameters such as frequency and duration to more accurately diagnose IBS.

Approximately 50 patients were randomized to each of four treatment groups: placebo or 16, 32 or 48 μg lubiprostone daily. Patients were asked to keep a log of their progress, including dose, abdominal symptoms like bloating and discomfort or pain, bowel movements (BMs) including frequency, straining, and consistency ratings, as well as the use of rescue medication.

Study results revealed significant differences between the active groups and placebo. Specifically, improvements in abdominal discomfort/pain and BM frequency rates in the lubiprostone-treated groups were more than twice those of the placebo group. At month one, decreases from baseline in abdominal discomfort (based on a 5-point scale) were 0.19, 0.45, 0.40, and 0.46 points in the placebo and three dosage groups, respectively. By month three, decreases from baseline were 0.34, 0.56, 0.59, and 0.53 points, respectively. Significant dose-dependent trends were observed for most of the symptoms. AE incidence and drop-out rates likewise increased with increasing dose.

"Overall, improvements in patient symptoms were observed for all doses, although highest in the group receiving the highest lubiprostone dose," said John Johanson, M.D., Rockford Gastroenterology Associates and lead study author. "The results demonstrate that lubiprostone is effective and well-tolerated as an option for patients with c-IBS, and further studies will confirm the optimal dose to maximize effect, but minimize potential safety issues."

Effect of Teduglutide on Patients with Moderate-Severe Crohn's Disease after 8 Weeks of Therapy: A Prospective Double-Blind, Placebo Controlled Trial [Abstract 686c]

Crohn's disease causes inflammation in the gastrointestinal tract. Average clinical remission rates are generally less than 40 percent in most clinical trials. In this study, a new therapy called teduglutide targets mucosal healing in addition to mucosal inflammation. The theory behind the use of this medication is to promote growth and repair of the injured tissues. In previous animal studies of inflammatory bowel disease, teduglutide has reduced inflamation and healed injured intestinal tissue.

In the exploratory study, 100 participants with active Crohn's disease were randomized and treated with one of three doses of teduglutide or placebo for eight weeks to determine rates of remission (CDAI less than 150) or clinical response (greater than 100 point decrease in CDAI from baseline).

While the trial did not evaluated dose-dependent comparisons, teduglutide was considered well-tolerated and effective in achieving remission and response in patients with moderate or severe Crohn's disease. Half of the teduglutide patients (53 percent) responded after two weeks of therapy and more than one-third (37 percent) experienced remission at the same time. After the full eight week regimen, researchers noted a clinical response in 61 percent of the treated group and remission in more than half (56 percent).

"These data note that use of teduglutide was safe and effective to induce remission of moderate to severe Crohn's disease as early as two weeks into therapy," said Alan Buchman, M.D., MSPH, Feinberg School of Medicine, Northwestern University, and lead study author. "We are encouraged that with additional trials to confirm the maximal effective dose, this therapy will offer a novel alternative to treat patients with Crohn's disease who have not responded to other therapies."

Teduglutide is an analog of the naturally occurring human peptide Glucagon Like Peptide-2 (GLP-2). GLP-2 is a peptide growth factor secreted in the distal intestine and is involved in regeneration, maintenance and repair of the intestine. Adverse events with teduglutide were generally self-limited, mild in nature and included abdominal pain and injection site reactions. There were no drug-related serious adverse events.

'"/>




Related medicine news :

1. Brain cells protected by new compounds
2. Body compounds can protect you against pain
3. Implantable devices to be powered by organosilicon compounds in the future
4. Skeleton May Sustain Damage Due To Use Of Anti-Depressants
5. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
6. Ambulance Services Cost £145 Each Time An Elderly Person Sustains A fal
7. Cancer-Causing Virus Synthesizes Protein To Help Sustain Itself In Host Cells
8. New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function
9. George Bush pledges 200 million dollars for AIDS relief
10. Acupuncture superseeds massage therapy for short term relief of pain
11. Acupuncture provides relief
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: